Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
ID: 350388Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $296K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350388

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-048.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity aimed at supporting small businesses in developing technologies to address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. This initiative, identified as the R43/R44 Small Business Innovation Research (SBIR) Grant, encourages innovative solutions that tackle root social issues such as housing stability and food insecurity, with the goal of enhancing access to treatment and improving public health outcomes. Eligible U.S.-based small business concerns can apply for funding, with project budgets reaching up to $306,872 for Phase I and $2,045,816 for Phase II, and a total funding commitment of $2 million for approximately six awards. The application period opens on February 13, 2024, and interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the funding announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-048.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-048-Full-Announcement.html
    It appears that there is no text provided for summarization. Please provide the document or text you would like summarized.
    RFA-DA-25-048.html
    The Department of Health and Human Services, in collaboration with the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), has issued a funding opportunity to support small business applications aimed at developing technologies to address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. The program, identified as R43/R44 Small Business Innovation Research (SBIR) Grant, includes provisions for phases I and II, allowing for clinical trials as an optional component. The purpose of this funding initiative is to foster the commercialization of innovative solutions that address root social needs associated with SUD, such as housing stability and food insecurity. Key dates include an open application date of February 13, 2024, with a funding commitment of $2 million for approximately six awards. Eligible applicants are U.S.-based small business concerns with less than 500 employees. Project budgets can reach up to $306,872 for Phase I and $2,045,816 for Phase II, with a project duration of up to six months for Phase I and two years for Phase II. The initiative emphasizes the importance of utilizing technology to enhance access to treatment and improve overall public health, urging applicants to propose innovative and effective strategies for combating the ongoing SUD crisis.
    Similar Opportunities
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at small business concerns (SBCs) to develop technologies that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. This initiative, titled "Seeking Products to Address Social Needs impacting SUD," invites applications for Small Business Technology Transfer (STTR) grants under phases I and II, with a total funding amount of $1.3 million available for four awards in FY 2025. The focus is on leveraging innovative technologies, such as telemedicine and mobile health applications, to improve conditions like housing instability and food insecurity that influence SUD outcomes. Interested applicants must comply with specific eligibility criteria and application guidelines, with a submission deadline of March 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html.
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) aimed at supporting research for the development of medications to prevent and treat substance use disorders (SUDs) and overdose. This initiative will focus on preclinical and clinical research studies that can rapidly advance candidate interventions toward regulatory approval or clinical adoption, encouraging collaborative efforts among experts in various fields such as pharmacology, toxicology, and clinical trials. While applications are not currently being solicited, interested small businesses are encouraged to begin forming partnerships and developing projects in anticipation of the opportunity, with an estimated synopsis post date of August 15, 2025, and a projected award date of July 1, 2026. For further inquiries, potential applicants can contact Drew Townsend, Ph.D., at drew.townsend@nih.gov or by phone at 301-443-4577.
    Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for substance use disorders (SUDs) (U54 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs)" under the U54 cooperative agreement mechanism. This initiative aims to establish a comprehensive drug development infrastructure that will support the research community in enhancing the substance use disorder drug development pipeline, focusing on the evaluation and validation of repurposed and repositioned drugs. The program is particularly important for fostering collaboration among researchers in pharmacology, toxicology, neuroscience, and related fields, providing essential services such as regulatory guidance and intellectual property consultations. The estimated total funding for this program is $2,500,000, with one award expected, and interested applicants are encouraged to prepare their proposals ahead of the estimated synopsis posting date on July 25, 2025, with applications anticipated to close by September 25, 2025. For further inquiries, potential applicants can contact Dr. Saravanan Karuppagounder at saravanan.karuppagounder@nih.gov or by phone at 301-480-9471.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC), is offering a Small Business Innovation Research (SBIR) Grant opportunity for United States small business concerns (SBCs) to submit applications for various phases of research and development, including Phase I, Phase II, Direct to Phase II, Fast-Track, and Phase IIB grants. Eligible applicants must possess the necessary research capabilities and technological expertise to support the R&D missions of the NIH and CDC, with a focus on health-related innovations. This funding opportunity is significant as it encourages collaboration among small businesses to advance health research, with applications expected to be solicited following the reauthorization of the SBIR program. Interested parties can reach out to the NIH SEED Office at SEEDinfo@nih.gov or call 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a closing date for applications anticipated on January 5, 2026.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a Specialized Center-Cooperative Agreement (U54) aimed at establishing a Dynamic and Adaptable Infrastructure for Drug Development and Outreach to enhance the research community's efforts in repurposing and repositioning medications for Substance Use Disorders (SUDs). The initiative seeks to support academic and biotech researchers by providing comprehensive drug development services, including regulatory guidance, intellectual property consultations, and technical support, while excluding clinical trials. This funding opportunity is critical for accelerating the drug development pipeline for SUDs, with NIH committing $2.5 million for one award in FY 2026, and applications are due by January 28, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-020.html.